PAVmed Inc. (NASDAQ: PAVM) has disclosed an updated ownership position showing that investor David S. Nagelberg beneficially owns 699,778 shares, representing 8.8% of the company’s outstanding common stock. The filing also shows that the David S. Nagelberg 2003 Revocable Trust owns 474,542 shares, or 5.9% of PAVmed. The disclosure puts a significant ownership position in focus as investors assess the company’s shareholder structure and potential implications of concentrated ownership.

Nagelberg Holds a Significant Ownership Position

As of August 13, 2026, Nagelberg beneficially owned 699,778 PAVmed shares, based on 7,995,918 shares outstanding. His reported position includes 474,542 shares held through the David S. Nagelberg 2003 Revocable Trust and an additional 225,236 shares held outside the Trust.

The combined position gives Nagelberg beneficial ownership of 8.8% of PAVmed. The Trust itself represents 5.9% of the company’s outstanding shares, making it a substantial individual ownership position relative to the company’s total share count.

Trust Structure Provides Voting and Dispositive Control

The ownership filing indicates that Nagelberg has sole voting and dispositive power over his 699,778 shares. The Trust likewise reports sole voting and dispositive power over its 474,542 shares, with no shared voting or dispositive power reported.

This distinction is important because beneficial ownership reflects both the economic interest in the shares and the ability to exercise control over them. The filing therefore indicates that the disclosed holdings are not subject to shared voting or investment authority with another party.

The ownership structure also clarifies that the Trust’s shares are controlled by Nagelberg. Together with the additional shares he owns outside the Trust, the arrangement produces the reported 8.8% beneficial ownership figure.

Why the Stake Matters to Investors

A nearly 9% ownership position can make a shareholder an important participant in a company’s capital structure, particularly when the number of outstanding shares is relatively limited. The disclosure does not, however, establish any specific strategic intention by Nagelberg beyond the ownership and control information reported in the filing.

Investors should therefore distinguish between what the filing confirms and what it does not. The disclosure establishes the size and control of the position, but the information provided does not indicate plans for acquisitions, sales, management changes or other corporate actions.

Market Outlook

The updated ownership disclosure puts PAVmed’s shareholder concentration firmly on the radar as investors monitor future filings for changes in Nagelberg’s position. Any material increase or reduction in his holdings could provide additional information about his investment stance, while changes in voting or dispositive arrangements could also become relevant. For now, the key fact is that Nagelberg controls a substantial 8.8% beneficial ownership position, giving his future activity potential significance for the company’s shareholder base and market perception.